ABOUT PROVISTA
Provista Diagnostics is focused on developing world-class diagnostics for indications in breast and gynecological cancers. When used in combination with standard of care, Provista's blood-based diagnostic tests provide real-time actionable results to improve the accuracy of cancer detection.
Read More
SCIENCE & TECHNOLOGY
Provista’s proprietary ProteoMark® Technology combines multiple Serum Protein Biomarkers and Tumor Associated Autoantibodies, with patient clinical data, to yield highly accurate diagnostic tests for women’s cancers.
Read More
DIAGNOSTIC PIPELINE
Provista is developing a robust pipeline of diagnostic blood tests to address unmet needs in women’s cancers including breast, ovarian, endometrial and HPV-associated cancers.
Read More
Diagnostic Dilemma
Dense breast tissue is normal and common among woman and it refers to the appearance of breast tissue on a mammogram. Dense tissue appears white on a mammogram similar to both benign and cancerous lumps leading to both false negative and false positive results.
Read More

NEWS

Sign Up for E-News
April 14, 2016

2016 American Society of Breast Surgeons

2016 American Society of Breast Surgeons Dates: Thursday, April 14 – Saturday, April 16 Location: Dallas, TX – Hilton Anatole Website: breastsurgeons.org Exhibitor Booth: 433
April 6, 2016

APR 6, 2016

Provista Diagnostics Announces New Chief Financial Officer and Expands Commercial Team Expertise NEW YORK, NY – April 6,, 2016 – Provista Diagnostics Inc., a company developing and commercializing molecular diagnostic, prognostic and monitoring tests for cancers affecting women, has promoted Uriel Kusiatin, M.B.A. to Chief Financial Officer and Kelly Gordon, […]
March 24, 2016

MAR 21, 2016

Provista Diagnostics Closes $5.25 Million Financing NEW YORK, NY – March 21, 2016 – Provista Diagnostics, Inc., a company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, today announced the closing of an additional $5.25 Million in preferred funding. This funding is comprised of capital […]